H-NMR (CDCl3, 400 MHz): δ 1.27 (t, J = 6.8 Hz, 3H), 1.42 (d, J = 7.2 Hz, 1H), 2.67 (ABX system, J = 15.6, 12.4 Hz, 1H), 2.94 (ABX system, J = 15.6, 11.6 Hz, 1H), 3.89 (AB system, J = 14.0 Hz, 1H), 3.95 (AB system, J = 14.0 Hz, 1H), 4.00-4.07 (m, 4H), 4.19 (q, J = 7.2 Hz, 1H), 6.78-7.37 (m, 9H). 116.5, 119.4, 122.0, 127.8, 128.4, 128.5, 128.6, 129.2, 129.7, 139.7, 157.7. -4-(1-phenylethyl)-2,3,4,5-tetrahydro-1,4,2λ 5 -benzoxazaphosphepine (12a). (S) 2,3,4,4,2λ 5 -benzoxazaphosphepine (12a).
S2 (S)-Diethyl-{[(2-hydroxybenzyl)(1-phenylethyl)amino]methyl}phosphonate (10a)
.
(S)-Diethyl-{[(2-hydroxybenzyl)(1-phenylethyl)amino]methyl}phosphonate (10a). HRMS (CI +
)
S4

Diethyl-[(2-hydroxyphenyl)(phenyl)methyl]phosphonate (11c)
Diethyl-[(2-hydroxyphenyl)(phenyl)methyl]phosphonate (11c). HRMS (CI +
S5 (S)-2,2,2-Triethoxy-4-(1-phenylethyl)-2,3,4,5-tetrahydro-1,4,2λ
5
-benzoxazaphosphepine (12a). 5 -benzoxazaphosphepine (12a). 1-phenylethyl]-2,3,4,5-tetrahydro-1,4 ,2-benzoxazaphosphepine 2-oxide (13d). 1-phenylethyl]-2,3,4,5-tetrahydro-1,4 ,2-benzoxazaphosphepine 2-oxide (13d). 1-phenylethyl]-2,3,4,5-tetrahydro-1,4 ,2-benzoxazaphosphepine 2-oxide (16b). 1-phenylethyl]-2,3,4,5-tetrahydro-1,4 ,2-benzoxazaphosphepine 2-oxide (15c). 
S6 (S)-2,2,2-Triethoxy-4-(1-phenylethyl)-2,3,4,5-tetrahydro-1,4,2λ
S7 (2R,S)-2-Ethoxy-(5S)-5-methyl-4-[(1ʹS)-1-phenylethyl]-2,3,4,5-tetrahydro-1,4,2-benzoxazaphosphepine 2-oxide (13b).
(2R,S)-2-Ethoxy-(5S)-5-methyl-4-[(1ʹS)
-
S9 (2R,S)-2-Ethoxy-(5S)-5-methyl-4-[(1ʹS)-1-phenylethyl]-
S11 (2S)-2-Ethoxy-(5S)-5-phenyl-4-[(1ʹS)-1-phenylethyl]-2,3,4,5-tetrahydro-1,4,2-benzoxazaphosphepine 2-oxide (13c).
(2S)-2-Ethoxy-(5S)-5-phenyl-4-[(1ʹS)-1-phenylethyl]-2,3,4,5-tetrahydro-1,4,2-benzoxazaphosphepine 2-oxide (13c).
S12 (2S)-2-Ethoxy-(5S)-5-phenyl-4-[(1ʹS)-1-phenylethyl]-2,3,4,5-tetrahydro-1,4,2-benzoxazaphosphepine 2-oxide (13c).
(2S)-2-Ethoxy-(5S)-5-phenyl-4-[(1ʹS)-1-phenylethyl]-2,3,4,5-tetrahydro-1,4,2-benzoxazaphosphepine 2-oxide (13c). HRMS (CI
S13 (2R)-2-Ethoxy-(5S)-5-phenyl-4-[(1ʹS)-1-phenylethyl]-2,3,4,5-tetrahydro-1,4,2-benzoxazaphosphepine 2-oxide (14c).
S14 (2R)-2-Ethoxy-(5S)-5-phenyl-4-[(1ʹS)-1-phenylethyl]-2,3,4,5-tetrahydro-1,4,2-benzoxazaphosphepine 2-oxide (14c).
S15 (2R,S)-2-Ethoxy-(5R)-5-(2-chlrophenyl)-4-[(1ʹS)-
S16 (2R,S)-2-Ethoxy-(5R)-5-(2-chlrophenyl)-4-[(1ʹS)-
(2R,S)-2-Ethoxy-(5R)-5-(2-chlrophenyl)-4-[(1ʹS)-1-phenylethyl]-2,3,4,5-tetrahydro-1,4,2-benzoxazaphosphepine 2-oxide (13d). HRMS (CI +
(2S)-2-Phenyl-4-[(1ʹS)-1-phenylethyl]-2,3,4,5-tetrahydro-1,4,2-benzoxazaphosphepine 2-oxide (16a).
S17 (2S)-2-Phenyl-4-[(1ʹS)-1-phenylethyl]-2,3,4,5-tetrahydro-1,4,2-benzoxazaphosphepine 2-oxide (16a).
(2S)-2-Phenyl-4-[(1ʹS)-1-phenylethyl]-2,3,4,5-tetrahydro-1,4,2-benzoxazaphosphepine 2-oxide (16a).
S18 (2S)-2-Phenyl-4-[(1ʹS)-1-phenylethyl]-2,3,4,5-tetrahydro-1,4,2-benzoxazaphosphepine 2-oxide (16a). HRMS (CI
(2R)-2-Phenyl-(5S)-5-methyl-4-[(1ʹS)-1-phenylethyl]-2,3,4,5-tetrahydro-1,4,2-benzoxazaphosphepine 2-oxide (15b).
S19 (2S)-2-Phenyl-(5S)-5-methyl-4-[(1ʹS)-1-phenylethyl]-2,3,4,5-tetrahydro-1,4,2-benzoxazaphosphepine 2-oxide (16b).
(2S)-2-Phenyl-(5S)-5-methyl-4-[(1ʹS)-1-phenylethyl]-2,3,4,5-tetrahydro-1,4,2-benzoxazaphosphepine 2-oxide (16b).
S20 (2S)-2-Phenyl-(5S)-5-methyl-4-[(1ʹS)-
S21 (2R,S)-2-phenyl-(5S)-5-phenyl-4-[(1ʹS)-1-phenylethyl]-2,3,4,5-tetrahydro-1,4,2-benzoxazaphosphepine 2-oxide (15c).
(2R,S)-2-phenyl-(5S)-5-phenyl-4-[(1ʹS)-
